KR20230006547A - 갈렉틴-3의 소분자 억제제 - Google Patents

갈렉틴-3의 소분자 억제제 Download PDF

Info

Publication number
KR20230006547A
KR20230006547A KR1020227042064A KR20227042064A KR20230006547A KR 20230006547 A KR20230006547 A KR 20230006547A KR 1020227042064 A KR1020227042064 A KR 1020227042064A KR 20227042064 A KR20227042064 A KR 20227042064A KR 20230006547 A KR20230006547 A KR 20230006547A
Authority
KR
South Korea
Prior art keywords
mmol
fluorophenyl
triazol
independently
conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227042064A
Other languages
English (en)
Korean (ko)
Inventor
프라사다 라오 잘라감
사티쉬 케사반 나이르
수쉴 제타난드 나라
마노란잔 판다
프라틱 데바스탈
앨리샤 레게이로-렌
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20230006547A publication Critical patent/KR20230006547A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020227042064A 2020-05-05 2021-05-04 갈렉틴-3의 소분자 억제제 Pending KR20230006547A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063020041P 2020-05-05 2020-05-05
US63/020,041 2020-05-05
PCT/US2021/030540 WO2021226002A1 (en) 2020-05-05 2021-05-04 Small molecule inhibitors of galectin-3

Publications (1)

Publication Number Publication Date
KR20230006547A true KR20230006547A (ko) 2023-01-10

Family

ID=76076509

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227042064A Pending KR20230006547A (ko) 2020-05-05 2021-05-04 갈렉틴-3의 소분자 억제제

Country Status (6)

Country Link
US (1) US12275720B2 (cg-RX-API-DMAC10.html)
EP (1) EP4146646A1 (cg-RX-API-DMAC10.html)
JP (1) JP7705884B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230006547A (cg-RX-API-DMAC10.html)
CN (1) CN115551855A (cg-RX-API-DMAC10.html)
WO (1) WO2021226002A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2631509A (en) * 2023-07-04 2025-01-08 Univ Liverpool Compositions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
ES2652488T3 (es) 2009-04-28 2018-02-02 Galecto Biotech Ab Nuevos inhibidores de galactósidos de galectinas
KR102231732B1 (ko) 2012-10-10 2021-03-23 갈렉틴 테라퓨틱스, 인크. 당뇨병성 신장병증 및 관련 질환의 치료를 위한 갈락토스 갈래의 탄수화물 화합물
IN2015DN02573A (cg-RX-API-DMAC10.html) 2012-10-31 2015-09-11 Galecto Biotech Ab
CA2970062C (en) 2015-01-30 2023-02-28 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
CA3000924A1 (en) 2015-11-09 2017-05-18 Galecto Biotech Ab Novel galactoside inhibitors of galectins
KR102626669B1 (ko) 2017-05-12 2024-01-17 갈랙틴 사이언시즈, 엘엘씨 질환의 예방 및 치료를 위한 화합물 및 이의 용도
CA3062649A1 (en) * 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the treatment of systemic insulin resistance disorders and the use thereof
EP3807290B1 (en) 2018-06-15 2022-03-30 Bristol-Myers Squibb Company Tetrahydropyran-based thiodisaccharide mimics as galectin-3 inhibitors

Also Published As

Publication number Publication date
WO2021226002A1 (en) 2021-11-11
JP7705884B2 (ja) 2025-07-10
US20230192672A1 (en) 2023-06-22
JP2023524996A (ja) 2023-06-14
CN115551855A (zh) 2022-12-30
EP4146646A1 (en) 2023-03-15
US12275720B2 (en) 2025-04-15

Similar Documents

Publication Publication Date Title
US11072626B2 (en) Small molecule inhibitors of Galectin-3
WO2019067702A1 (en) INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3
US20250230138A1 (en) Compounds having a t-structure formed by at least four cycles for use in the treatment of cancer and other indications
EP1067123A1 (en) Nitrogenous heterocyclic compounds
JP2016537369A (ja) カゼインキナーゼ1d/e阻害剤としての置換された4,5,6,7−テトラヒドロピラゾロ[1,5−a]ピラジン誘導体
KR102967859B1 (ko) 갈렉틴-3의 소분자 억제제
KR20210150485A (ko) 갈렉틴-3의 소분자 억제제
ES2912499T3 (es) Miméticos de tiodisacáridos a base de tetrahidropirano como inhibidores de galectina-3
US12275720B2 (en) Small molecule inhibitors of galectin-3
US20250313574A1 (en) Sialic acid derivatives and methods of using same
CN116981669B (zh) 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途
EP4157833A1 (en) Galectin-3 inhibitors
US12275718B2 (en) Small molecule inhibitors of galectin-3
KR20230009433A (ko) 갈렉틴-3의 소분자 억제제
TW202615040A (zh) Glp-1受體促效劑及其用途
TW202608868A (zh) 作為egfr抑制劑之雜環化合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000